• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by GRI Bio Inc.

    5/5/25 7:35:23 AM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRI alert in real time by email
    424B5 1 gri-atmxprospectussuppleme.htm 424B5 Document


    Filed pursuant to Rule 424(b)(5)
    Registration No. 333-279348

    PROSPECTUS SUPPLEMENT
    (To Prospectus Supplements Dated May 20, 2024, July 19, 2024, July 26, 2024 and December 20, 2024, to Prospectus Dated May 16, 2024)
    GRI BIO, INC.
    Up to $1,670,956
    Common Stock
    This prospectus supplement amends, supplements, and supersedes certain information contained in the prospectus supplement dated May 20, 2024, and its accompanying prospectus dated May 16, 2024, as supplemented by our prospectus supplements dated July 19, 2024, July 26, 2024 and December 20, 2024 (collectively, the “Prior Prospectuses”), relating to the offer and sale of our common stock, par value $0.0001 per share (the “Common Stock”) through H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent, in “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, pursuant to the At the Market Offering Agreement with Wainwright dated as of May 20, 2024 (the “Sales Agreement”).
    As of May 5, 2025, the aggregate market value of our outstanding Common Stock held by non-affiliates (the “public float”) calculated for purposes of General Instruction I.B.6 of Form S-3, was approximately $15.8 million based on 1,914,246 shares of outstanding Common Stock as of May 5, 2025, of which 471 shares were held by affiliates, and a price of $8.27 per share, which was the price at which our Common Stock was last sold on the Nasdaq Capital Market on March 21, 2025.
    We have sold an aggregate of approximately $3,604,683 of shares of Common Stock pursuant to General Instruction I.B.6 of Form S-3 during the prior 12-calendar month period that ends on and includes the date of this prospectus supplement.
    We are filing this prospectus supplement to amend the Prior Prospectuses to update the amount of shares we are eligible to sell pursuant to such prospectus. We are increasing the amount of shares of Common Stock we may offer and sell under the Sales Agreement to an aggregate offering price of up to $1,670,956 from time to time through Wainwright, which does not include the shares of Common Stock having an aggregate gross sales price of approximately $3,604,683 that were sold pursuant to the Prior Prospectuses to date. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding one-third of our public float in any 12-month calendar period so long as our public float remains below $75.0 million. In the event that we may sell additional amounts under the Sales Agreement, we will file another prospectus supplement prior to making such additional sales.
    Our Common Stock is listed on the Nasdaq Capital Market under the symbol “GRI”. On May 2, 2024, the last reported sale price of our Common Stock on the Nasdaq Capital Market was $2.10 per share.
    Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties under the heading “Risk Factors” on page 5 of the prospectus dated



    May 16, 2024, on page S-7 of the prospectus supplement filed on May 20, 2024, and the other documents that are incorporated by reference to this prospectus supplement.
    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this prospectus is accurate or complete. Any representation to the contrary is a criminal offense.
    H.C. Wainwright & Co.
    The date of this prospectus supplement is May 5, 2025



    Get the next $GRI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRI

    DatePrice TargetRatingAnalyst
    12/9/2024$10.00Buy
    H.C. Wainwright
    More analyst ratings

    $GRI
    Leadership Updates

    Live Leadership Updates

    See more
    • Connect Biopharma Announces New Leadership and Chair of the Board of Directors

      Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life science executive David Szekeres appointed as PresidentKleanthis G. Xanthopoulos, Ph.D. appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cel

      6/12/24 4:15:00 PM ET
      $CNTB
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio (NASDAQ: GRI) Announces Appointment of Leanne Kelly as Chief Financial Officer

      - Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm LA JOLLA, CA, April 25, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the appointment of Leanne Kelly as its Chief Financial Officer. Ms. Kelly is an accomplished financial executive with over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce

      4/25/23 8:45:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRI
    SEC Filings

    See more
    • GRI Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - GRI Bio, Inc. (0001824293) (Filer)

      5/23/25 7:16:47 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by GRI Bio Inc.

      424B5 - GRI Bio, Inc. (0001824293) (Filer)

      5/23/25 7:14:51 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by GRI Bio Inc.

      10-Q - GRI Bio, Inc. (0001824293) (Filer)

      5/15/25 8:38:34 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Kelly Leanne

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:58:28 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Chaturvedi Vipin

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:58:17 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Hertz Walter Marc

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:58:06 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results

      Data presented at the 2025 American Thoracic Society (ATS) International Conference Pre-clinical and interim clinical results underscore GRI-0621's potential to have both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis Results from 6-week interim analysis (n=24) in ongoing Phase 2a study of GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) anticipated in Q2 2025 LA JOLLA, CA, May 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pr

      5/22/25 8:00:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio to Participate in the Virtual Investor Closing Bell Series

      Live webcast on Wednesday, May 28th at 4:00 PM ET LA JOLLA, CA, May 21, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in the Virtual Investor Closing Bell Series on Wednesday, May 28, 2025 at 4:00 PM ET. As part of the event, Dr. Hertz will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submi

      5/21/25 9:15:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

      Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 21, 2025 at 2:40 PM ET. Click here to register for the event. A live webcast of the fireside chat will be accessible

      5/16/25 9:15:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on GRI Bio with a new price target

      H.C. Wainwright initiated coverage of GRI Bio with a rating of Buy and set a new price target of $10.00

      12/9/24 7:50:37 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care